Spatial Transcriptomic Signature of Progressive Fibrosis in Human MASLD: Role of Senescence and Metabolic Reprogramming.
Hani VuiD, Yuliangzi SuniD, Zherui XiongiD, Daniel E. Radford‐SmithiD, Andrew CauseriD, Christian Maximilian NefzgeriD, Eoin Daniel O'SullivaniD, Matthew J. WattiD, Grant A. RammiD, Andrew Donald CloustoniD, Katharine M. IrvineiD, Quan Hoang NguyeniD, Elizabeth Ellen PowelliD
Abstract
Granular detail about the location and nature of liver cell interactions and the metabolic, inflammatory and fibrogenic pathways driving progressive fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) is needed to deliver novel therapeutic targets. Here we used spatial transcriptomic data from human MASLD liver biopsies to identify the major cell types and their potential interconnected activities within specific tissue regions across the spectrum of MASLD. Gene expression data were generated using 10X Genomics Visium technology from 33 formalin-fixed paraffin-embedded liver biopsy samples and overlaid with annotated anatomical regions. Differential gene expression (DEG) and pathway analyses, cellular deconvolution and ligand-receptor interactions were conducted for each annotated anatomical category, with specific protein expression validated using CODEX spatial proteomics and immunohistochemistry staining. Unsupervised gene expression data grouped the annotated spots into 2 main clusters enriched for early/intermediate vs late fibrosis and transcriptome-based cellular deconvolution was well aligned with annotated histopathological features. In addition to extracellular matrix/receptor interactions and immune cell recruitment and trafficking, several genes encoding immunoglobulins were highly upregulated in late-stage fibrosis and were spatially associated with a senescence signature. Upregulated DEGs for early/intermediate-stage fibrosis were significantly enriched for metabolic pathways, oxidative phosphorylation and fatty acid metabolism. In contrast glycolysis genes were strongly co-expressed with late stage fibrosis. MASLD progression is accompanied by a decline in normal liver metabolic function and significant reprogramming of metabolic fuel utilisation. The spatial association of a senescence signature with expression of genes encoding immunoglobulins and complement has been linked to aging and is associated with progressive fibrosis. This work provides a valuable discovery dataset spanning different stages of human liver fibrosis and highlights the complex crosstalk between metabolic perturbations and inflammation underpinning fibrosis progression.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Global molecular landscape of early MASLD progression in obesity
Qing Zhao, William De Nardo, … Philipp Kaldis·eLifePeer-reviewed·Mar 23, 2026
- MegaMASLD: An interactive platform for exploring stratified transcriptomic signatures in MASLD progression
Hong Sheng Cheng, Damien Chua, … Nguan Soon Tan·bioRxiv·Jul 21, 2024
- Network-based meta-analysis maps stage-dependent molecular programs in MASLD through MASLD-META NETWORK application
Eren Kumak, Thomas Darde, Özlen Konu·bioRxiv·Aug 31, 2026
- Decoding MASLD Progression: A Molecular Trajectory-Based Framework for Modelling Disease Dynamics
Ioannis Kamzolas, Thodoris Koutsandreas, … Evangelia Petsalaki·bioRxiv·Jan 14, 2025
- Mapping vascular plasticity in liver fibrogenesis identifies novel fibrosis-associated endothelial cells in early-stage liver disease
Christina Gkantsinikoudi, Joshua P. Dignam, … Neil Dufton·bioRxiv·Mar 19, 2026
- Myeloid cells contribute to bystander CD8 T cell accumulation in metabolic-associated steatohepatitis and are sufficient for fibrosis
Cynthia Lebeaupin, Katelyn L. Donahue, … Thomas Fabre·bioRxiv·Jan 20, 2026